デフォルト表紙
市場調査レポート
商品コード
1719166

生物学的皮膚代替物市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、用途別、エンドユーザー別、地域別、競合別セグメント、2020-2030F

Biological Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region and Competition, 2020-2030F


出版日
ページ情報
英文 185 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

生物学的皮膚代替物市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、用途別、エンドユーザー別、地域別、競合別セグメント、2020-2030F
出版日: 2025年04月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生物学的皮膚代替物の世界市場規模は、2024年に3億4,147万米ドルとなり、2030年には5億5,850万米ドルに達すると予測され、予測期間中のCAGRは8.52%で成長すると予測されています。

市場成長の原動力は、特に糖尿病性潰瘍、褥瘡、熱傷などの慢性創傷に対する高度創傷治療需要の増加です。生物学的皮膚代替物は、治癒を促進し、感染リスクを最小限に抑え、美容的な結果を改善することで、従来の創傷ケアに代わる、より効果的で生物学的適合性の高い選択肢を提供します。この市場は、再生医療、組織工学、幹細胞を用いた治療法などの技術進歩によってさらに活性化しています。ヘルスケアシステムが臨床転帰の改善と長期療養費の削減を重視する中、特に複雑な創傷や治癒しない創傷の管理において、生物学的皮膚代替物が支持を集めています。外科手術の増加、人口の高齢化、個別化治療の革新が引き続き市場の拡大を後押ししています。

市場概要
予測期間 2026-2030
市場規模:2024年 3億4,147万米ドル
市場規模:2030年 5億5,850万米ドル
CAGR:2025年~2030年 8.52%
急成長セグメント 慢性創傷
最大市場 北米

市場促進要因

再生医療の進歩

主な市場課題

高いコストと限られたアクセス性

主な市場動向

個別化されたオーダーメイドソリューション

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の生物学的皮膚代替物市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 種類別(ヒトドナー組織由来製品、無細胞動物由来製品、生合成製品)
    • 用途別(慢性創傷、急性創傷)
    • エンドユーザー別(病院・診療所、外来診療センター、その他)
    • 企業別(2024)
    • 地域別
  • 市場マップ

第6章 北米の生物学的皮膚代替物市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の生物学的皮膚代替物市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の生物学的皮膚代替物市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の生物学的皮膚代替物市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの生物学的皮膚代替物市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Organogenesis Inc.
  • Integra LifeSciences Corporation
  • Smith & Nephew, plc
  • Tissue Regenix Group
  • MIMEDX Group, Inc.
  • Stryker Corporation
  • Vericel Corporation
  • 3M Company
  • Bio-Tissue, Inc.
  • Stratatech Corporation

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 15618

The Global Biological Skin Substitutes Market was valued at USD 341.47 million in 2024 and is projected to reach USD 558.50 million by 2030, growing at a CAGR of 8.52% during the forecast period. Market growth is being driven by increasing demand for advanced wound care, particularly for chronic wounds such as diabetic ulcers, pressure sores, and burn injuries. Biological skin substitutes offer a more effective and biologically compatible alternative to conventional wound care by enhancing healing, minimizing infection risks, and improving cosmetic outcomes. The market is further fueled by technological progress in regenerative medicine, tissue engineering, and stem cell-based therapies. As healthcare systems emphasize improved clinical outcomes and reduced long-term care costs, biological skin substitutes are gaining traction, especially in the management of complex or non-healing wounds. Increasing surgical procedures, an aging population, and innovation in personalized therapies continue to bolster market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 341.47 Million
Market Size 2030USD 558.50 Million
CAGR 2025-20308.52%
Fastest Growing SegmentChronic Wounds
Largest MarketNorth America

Key Market Drivers

Advancements in Regenerative Medicine

The growing integration of regenerative medicine in wound care is a key driver of the biological skin substitutes market. Chronic wounds such as diabetic foot ulcers and venous leg ulcers often resist healing through traditional methods. Regenerative medicine-leveraging stem cells, growth factors, and engineered tissue-enables the creation of substitutes that promote faster, more effective tissue repair. FDA approvals of various regenerative therapies highlight their clinical potential. These technologies improve healing outcomes and reduce complications, particularly among elderly patients and those with chronic conditions. The focus on biologically active, personalized solutions for difficult-to-heal wounds underscores the increasing relevance of regenerative therapies in the global market.

Key Market Challenges

High Costs and Limited Accessibility

The high production costs associated with biological skin substitutes pose a substantial barrier to market growth. These products require sophisticated manufacturing processes, such as cell harvesting and tissue engineering, which elevate their price. In low-income and resource-constrained healthcare systems, these costs often place advanced wound care out of reach. Additionally, infrastructure challenges in storing and administering these products-particularly in rural and under-resourced settings-limit their accessibility. Even in developed countries, limited insurance reimbursement and high out-of-pocket costs deter adoption. Addressing affordability and expanding access will be crucial for broader market penetration and improved patient outcomes worldwide.

Key Market Trends

Personalized and Custom-Made Solutions

Personalized wound care is emerging as a major trend in the biological skin substitutes market. Increasingly, treatments are being tailored to individual patient profiles, including autologous skin grafts derived from a patient's own cells. This reduces the risk of immune rejection and enhances healing, particularly for complex wounds or burn injuries. The growth of 3D bioprinting is further enabling the creation of skin substitutes that replicate the structure and functionality of natural skin. These personalized, patient-specific solutions offer superior biological compatibility and regeneration potential. As precision medicine gains momentum in wound care, the demand for custom skin substitutes is expected to accelerate significantly.

Key Market Players

  • Organogenesis Inc.
  • Integra LifeSciences Corporation
  • Smith & Nephew, plc
  • Tissue Regenix Group
  • MIMEDX Group, Inc.
  • Stryker Corporation
  • Vericel Corporation
  • 3M Company
  • Bio-Tissue, Inc.
  • Stratatech Corporation

Report Scope:

In this report, the Global Biological Skin Substitutes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biological Skin Substitutes Market, By Type:

  • Human Donor Tissue-Derived Products
  • Acellular Animal Derived Products
  • Biosynthetic Products

Biological Skin Substitutes Market, By Application:

  • Chronic Wounds
  • Acute Wounds

Biological Skin Substitutes Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Biological Skin Substitutes Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biological Skin Substitutes Market.

Available Customizations:

Global Biological Skin Substitutes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

for export?

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Biological Skin Substitutes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Human Donor Tissue-Derived Products, Acellular Animal Derived Products, Biosynthetic Products)
    • 5.2.2. By Application (Chronic Wounds, Acute Wounds)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Biological Skin Substitutes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biological Skin Substitutes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Biological Skin Substitutes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Biological Skin Substitutes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Biological Skin Substitutes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Biological Skin Substitutes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Biological Skin Substitutes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Biological Skin Substitutes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Biological Skin Substitutes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Biological Skin Substitutes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Biological Skin Substitutes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biological Skin Substitutes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Biological Skin Substitutes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Biological Skin Substitutes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Biological Skin Substitutes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Biological Skin Substitutes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Biological Skin Substitutes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biological Skin Substitutes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Biological Skin Substitutes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Biological Skin Substitutes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Biological Skin Substitutes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biological Skin Substitutes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Biological Skin Substitutes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Biological Skin Substitutes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Organogenesis Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Integra LifeSciences Corporation
  • 14.3. Smith & Nephew, plc
  • 14.4. Tissue Regenix Group
  • 14.5. MIMEDX Group, Inc.
  • 14.6. Stryker Corporation
  • 14.7. Vericel Corporation
  • 14.8. 3M Company
  • 14.9. Bio-Tissue, Inc.
  • 14.10. Stratatech Corporation

15. Strategic Recommendations

16. About Us & Disclaimer